The global Huntington’s disease community was enthralled last week with the announcement of Ionis Pharmaceuticals’ “top line” results from their first-in-human trial of a new drug for Huntington’s disease in which they stated that the drug “substantially exceeded” all expectations. The trial was led by Prof Sarah Tabrizi from University College London who was in […]
via The Huntington’s Disease Drug Trial – Why all the Hope? — Neuroscience Ireland
